This document summarizes global trends in drug pricing, reimbursement, and market access. It provides data on pharmaceutical R&D spending, employment, sales, and other metrics for key global markets including the US, Europe, and Canada. It then discusses factors that impact drug pricing internationally and in Canada, such as external price referencing and currency fluctuations. Emerging trends in global cost containment like delisting treatments, off-label prescribing, and biosimilar uptake that could affect the Canadian market are also examined based on a survey of international and Canadian industry and payer perspectives.
The biotechnology industry had an unprecedented year in 2014, reaching new highs in revenues, R&D spending, profits, financing amounts, and market capitalization. Strong product sales and approvals helped boost investor sentiment and company valuations. A surge in IPOs and follow-on financings provided the industry with historic levels of capital to fund innovation.
Sanofi reported results for Q3 2015 with sales growing 3.4% at constant exchange rates. Business EPS grew 6.1% at constant exchange rates. While diabetes sales declined 6.6% due to lower sales of Lantus in the US, other businesses such as Genzyme, vaccines, and Merial showed solid sales growth. Praluent was launched in the US and Europe for cholesterol treatment.
The document summarizes CPG industry performance in 2012, finding that unit sales were largely flat while dollar sales growth was driven by inflation. Channel performance varied, with convenience outperforming other channels. Categories related to health, beauty and home cooking saw stronger growth. Looking ahead, the recovery faces challenges while private label growth trends differ across channels and departments.
The presentation provides an overview of Hershey's business model and strategies to sustain momentum and deliver shareholder returns. Hershey has a growing portfolio of beloved brands that hold strong US market shares. It has unmatched capabilities connecting it to consumers through customer strategies, data analytics, agile supply chain, and precision consumer messaging. Hershey also has a dynamic workforce and takes a long-term view in its growth, focusing on environmental, social and governance goals. Its strategies are aimed at balanced long-term sales growth and margin expansion to deliver consistent earnings growth and healthy cash flow.
The document discusses research and development (R&D) ratios and Sanofi-Aventis' R&D expenditures over time. It notes that Sanofi-Aventis was formed through the merger of Sanofi and Aventis in 2004. From 2001-2004, both companies maintained an R&D intensity of around 16%, but in 2004 after the merger, R&D intensity increased dramatically to 50% as R&D expenditures rose significantly that year. The document also presents Sanofi-Aventis' continued R&D spending and intensity levels from 2004-2008.
François-Xavier Roger, CFO of Nestlé, discusses the company's focus on sustainability leadership and creating shared value. Nestlé has a proven track record of margin improvement and cost savings over the past 4 years. Sustainability investments of CHF 3.2 billion from 2020-2025 are expected to be earnings-neutral through a similar resource generation model. Sustainability is integral to Nestlé's growth strategy and consumer expectations, including increasing investments in climate action, sustainable packaging, and plant-based products.
Dirk Van de Put, CEO of Mondelēz International, presented at CAGNY 2019. He outlined the company's strategy to drive accelerated growth by adopting a more consumer-centric approach, focusing on operational excellence, and building a winning culture. Van de Put projected 3%+ organic net revenue growth, high single-digit adjusted EPS growth at constant currency, dividend growth above adjusted EPS growth, and over $3 billion in annual free cash flow as part of an attractive long-term financial outlook. He also highlighted strategic initiatives around global and local brands, new marketing approaches, agile innovation, expanding channels and key markets, and partnerships and M&A to support continued growth.
Pfizer at Citi Global Health Care Conferencefinance5
The document is a presentation from Pfizer's CFO at a healthcare conference in May 2008. It summarizes Pfizer's strategies to: 1) maximize revenues from existing, new, and diverse product sources; 2) establish a lower, more flexible cost base; and 3) innovate its business model. The presentation provides details on optimizing Pfizer's patent-protected portfolio, capitalizing on established products, growing in emerging markets, proven cost management track record, and 2008 financial guidance.
The biotechnology industry had an unprecedented year in 2014, reaching new highs in revenues, R&D spending, profits, financing amounts, and market capitalization. Strong product sales and approvals helped boost investor sentiment and company valuations. A surge in IPOs and follow-on financings provided the industry with historic levels of capital to fund innovation.
Sanofi reported results for Q3 2015 with sales growing 3.4% at constant exchange rates. Business EPS grew 6.1% at constant exchange rates. While diabetes sales declined 6.6% due to lower sales of Lantus in the US, other businesses such as Genzyme, vaccines, and Merial showed solid sales growth. Praluent was launched in the US and Europe for cholesterol treatment.
The document summarizes CPG industry performance in 2012, finding that unit sales were largely flat while dollar sales growth was driven by inflation. Channel performance varied, with convenience outperforming other channels. Categories related to health, beauty and home cooking saw stronger growth. Looking ahead, the recovery faces challenges while private label growth trends differ across channels and departments.
The presentation provides an overview of Hershey's business model and strategies to sustain momentum and deliver shareholder returns. Hershey has a growing portfolio of beloved brands that hold strong US market shares. It has unmatched capabilities connecting it to consumers through customer strategies, data analytics, agile supply chain, and precision consumer messaging. Hershey also has a dynamic workforce and takes a long-term view in its growth, focusing on environmental, social and governance goals. Its strategies are aimed at balanced long-term sales growth and margin expansion to deliver consistent earnings growth and healthy cash flow.
The document discusses research and development (R&D) ratios and Sanofi-Aventis' R&D expenditures over time. It notes that Sanofi-Aventis was formed through the merger of Sanofi and Aventis in 2004. From 2001-2004, both companies maintained an R&D intensity of around 16%, but in 2004 after the merger, R&D intensity increased dramatically to 50% as R&D expenditures rose significantly that year. The document also presents Sanofi-Aventis' continued R&D spending and intensity levels from 2004-2008.
François-Xavier Roger, CFO of Nestlé, discusses the company's focus on sustainability leadership and creating shared value. Nestlé has a proven track record of margin improvement and cost savings over the past 4 years. Sustainability investments of CHF 3.2 billion from 2020-2025 are expected to be earnings-neutral through a similar resource generation model. Sustainability is integral to Nestlé's growth strategy and consumer expectations, including increasing investments in climate action, sustainable packaging, and plant-based products.
Dirk Van de Put, CEO of Mondelēz International, presented at CAGNY 2019. He outlined the company's strategy to drive accelerated growth by adopting a more consumer-centric approach, focusing on operational excellence, and building a winning culture. Van de Put projected 3%+ organic net revenue growth, high single-digit adjusted EPS growth at constant currency, dividend growth above adjusted EPS growth, and over $3 billion in annual free cash flow as part of an attractive long-term financial outlook. He also highlighted strategic initiatives around global and local brands, new marketing approaches, agile innovation, expanding channels and key markets, and partnerships and M&A to support continued growth.
Pfizer at Citi Global Health Care Conferencefinance5
The document is a presentation from Pfizer's CFO at a healthcare conference in May 2008. It summarizes Pfizer's strategies to: 1) maximize revenues from existing, new, and diverse product sources; 2) establish a lower, more flexible cost base; and 3) innovate its business model. The presentation provides details on optimizing Pfizer's patent-protected portfolio, capitalizing on established products, growing in emerging markets, proven cost management track record, and 2008 financial guidance.
The document provides an overview of The Coca-Cola Company's 2020 outlook. It discusses non-GAAP financial measures and the inability to reconcile certain projected 2020 metrics to GAAP due to uncertainties. It also notes forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from expectations.
The document summarizes a presentation given at the CAGNY conference by J.P. Bilbrey, President and CEO of The Hershey Company. It discusses the company's strategies to drive predictable, profitable, and sustainable results globally through international expansion, portfolio growth, delivering strong North American performance, innovation, and leveraging knowledge and capabilities. It provides an outlook for 2015 with a focus on net sales growth, adjusted gross and operating margin expansion, and adjusted earnings per share growth.
The document provides an overview of Sanofi's Q4 and full year 2021 results. Key highlights include:
- Global sales grew 7.1% in 2021 to €37.7 billion, driven by strong growth of Specialty Care which became the largest business unit.
- Dupixent sales increased 53% in Q4 to €1.55 billion, with growth across all regions. Prurigo nodularis phase 3 trials showed significant improvements.
- Vaccines sales declined 6.5% in Q4 due to earlier seasonal flu shipments, while full year flu vaccine sales reached record levels in 2021.
- Planned launches of sutimlimab for CAD in 2022 and olp
The document outlines SQM, a global mining company based in Chile, and discusses its business lines including being a leading producer of potassium nitrate, iodine, lithium, and industrial chemicals. It highlights SQM's unique natural resources in Chile, sales to over 115 countries, solid financial position, and capital expenditure plans to increase production capacities of various products.
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered strong financial results in 2008, meeting guidance targets for sales growth and adjusted earnings per share.
- The company's three business segments - pharmaceuticals, medical devices & diagnostics, and consumer - all experienced sales growth in 2008.
- J&J is advancing its pharmaceutical, medical device, and consumer product pipelines with numerous new product filings planned for 2009-2010.
- While macroeconomic uncertainties may impact 2009 performance, J&J is well positioned due to its diversified business portfolio and continued investment in R&D and new product development.
GNC presented at the William Blair Growth Stock Conference on June 14, 2011. The presentation provided an overview of GNC's business segments including retail, franchise, and manufacturing/wholesale. It highlighted GNC's leading market position in health and wellness retailing in the US and globally. The presentation also discussed positive macro trends driving industry growth, such as increasing focus on health and wellness, and how GNC is well-positioned to capitalize on these trends through its premium branded products and knowledgeable customer service.
We are given a buy recommendation for Gilead Sciences. While Gilead has seen significant revenue growth in recent years due to two hepatitis C drugs, their future revenue growth is expected to slow. Speculation around future performance and new competition has led the market to undervalue Gilead. However, the company maintains a broad product portfolio and pipeline, and low costs provide strong margins. If Gilead can successfully manage competition through new drugs and pricing strategies, while pursuing M&A, they are positioned to outperform current market expectations.
Merck announced second-quarter 2005 earnings per share of 33 cents, down from 79 cents in 2004 due to a $640 million net tax charge. Excluding this charge, EPS were 62 cents. Worldwide sales were $5.5 billion, down 9% from 2004 due to the Vioxx withdrawal. Merck anticipates third-quarter EPS of 61-65 cents and full-year 2005 EPS of $2.44-$2.52 excluding the tax charge. Major drug franchises like Singulair, Fosamax, Cozaar, and Zocor maintained or grew market share. Merck's vaccine and diabetes drug pipelines progressed with regulatory submissions.
Bristol-Myers Squibb reported strong fourth quarter 2008 results, with net sales increasing 4% driven by key products like Plavix, Abilify, and Orencia. Gross profit margins improved significantly due to cost improvements and favorable product mix. Research and development expenses increased to fund new collaborations. The company provided guidance for 2009 GAAP EPS of $1.58-$1.73 and non-GAAP EPS of $1.85-$2.00, expecting revenue growth and further margin improvements. Bristol-Myers will continue business development efforts and advancing its pipeline to create long-term shareholder value.
The document discusses Coca-Cola's strategy and investments to achieve long-term profitable growth through 2020. It highlights growth in emerging markets, executing strategies in developed markets like North America, and investing in core brands and system capabilities globally. Coca-Cola aims to capture opportunities from rising global prosperity while driving sustainable growth across geographic segments.
Laurent Freixe presented on driving sustainable value creation in Zone Americas. Some key points:
1) Zone Americas has a strong footprint across North and Latin America with $37.7 billion in sales and over 90,000 employees.
2) Zone Americas has accelerated organic growth from 3.4% in 2017 to 4.8% in 2020 while reducing structural costs and increasing underlying operating profit margin.
3) Sustainability is at the core of the strategic framework, including initiatives from farm to fork and beyond like regenerative agriculture, renewable energy, and reducing water usage.
The 2008 annual report summarizes Agilent's strong financial performance in fiscal year 2008, with 7% revenue growth to $5.8 billion and increases in operating profit, earnings per share, and return on invested capital. It also discusses Agilent's proactive response to the economic slowdown in the second half of 2008 through cost controls and investment in innovative measurement solutions. The report outlines Agilent's leadership in electronic and bio-analytical measurement and strategy to focus on growth areas like life science, while managing declines in manufacturing test markets during the economic downturn.
Play to Win Q2 2021 Results
- Sanofi reported sales of €8.7 billion in Q2 2021, up 12% year-over-year, and business EPS of €1.38, up 16% year-over-year.
- Dupixent sales grew 57% year-over-year to €1.2 billion, driven by strong performance in both the US and ex-US markets.
- Vaccines sales increased by double digits to €1 billion in Q2 2021 compared to the same period in 2020.
- The presentation reviewed Sanofi's progress on priority R&D assets and initiatives to increase diversity and inclusion in the workplace.
This document summarizes Sanofi's Sustaining Innovation Analyst Day held on December 13, 2017 in Paris. It outlines Sanofi's strategic focus on sustaining innovation in R&D through developing high-value projects, improving launch pipeline and portfolio prioritization processes. Sanofi's R&D model focuses on key disease areas like immunology, oncology, rare diseases, diabetes and vaccines. The presentation highlights 9 potential product submissions in the next 18 months and over 10 new pivotal trials expected to start in the next 12 months. Sanofi aims to financially discipline its R&D investments based on rigorous project prioritization methodology.
The document is a summary of the 2014 Food & Beverage Industry Study by WeiserMazars LLP. It finds that most food and beverage companies anticipated sales growth in 2013 and 2014 due to new customers and improved sales performance. Companies expect costs like labor to rise in 2014. The top concerns for companies are rising commodity costs and food safety. Most companies are prepared for Affordable Care Act requirements and are focusing on process improvement and digital marketing.
This document contains forward-looking statements regarding Sanofi's strategic outlook, key growth drivers, and pipeline of potential transformative therapies. It discusses the significant growth potential of Dupixent across type 2 inflammatory diseases, with an ambition to achieve over €10 billion in peak sales. Vaccines are also highlighted as an expected mid-to-high single-digit growth driver through 2025. The pipeline includes potential first-in-class or best-in-class therapies for diseases like multiple sclerosis, respiratory syncytial virus, and breast cancer that could transform patient care if approved.
This document provides a safe harbor statement noting that certain statements made could constitute forward-looking statements regarding expectations of future operating results and events. It cautions that actual results could differ materially from expectations due to various risks and uncertainties. It also outlines Monster Beverage Corporation's commitment to employee health and safety during the COVID-19 pandemic, including closing offices, providing necessary equipment for remote work, enhanced safety protocols, and increased employee communication and support programs. Finally, it provides data on the company's and category's financial performance in the total US market for the 13 weeks ending December 26, 2020.
Social media allows for two-way communication and dialogue rather than one-way broadcasts. It has seen a rapid rise with key sites like Friendster, MySpace, Facebook, Twitter, and others growing exponentially in their early years. Marketers are drawn to social media because it enables conversations with consumers and viral word-of-mouth at low cost compared to traditional media. However, it also poses challenges for brands to control their message and reputation across fragmented networks.
The document outlines the process for developing and expanding a healthcare provider network. It involves assessing the target market, identifying necessary provider types, designing products to meet regulatory and customer needs, recruiting providers, completing contracts, and marketing the new network. Key steps include determining locations and populations, assessing competitors, recruiting primary care and specialists, complying with regulations, establishing payment rates, collecting signed contracts, and launching promotional materials and events. The goal is to build a network that offers customers valuable healthcare options and providers an attractive partnership.
The document provides an overview of The Coca-Cola Company's 2020 outlook. It discusses non-GAAP financial measures and the inability to reconcile certain projected 2020 metrics to GAAP due to uncertainties. It also notes forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from expectations.
The document summarizes a presentation given at the CAGNY conference by J.P. Bilbrey, President and CEO of The Hershey Company. It discusses the company's strategies to drive predictable, profitable, and sustainable results globally through international expansion, portfolio growth, delivering strong North American performance, innovation, and leveraging knowledge and capabilities. It provides an outlook for 2015 with a focus on net sales growth, adjusted gross and operating margin expansion, and adjusted earnings per share growth.
The document provides an overview of Sanofi's Q4 and full year 2021 results. Key highlights include:
- Global sales grew 7.1% in 2021 to €37.7 billion, driven by strong growth of Specialty Care which became the largest business unit.
- Dupixent sales increased 53% in Q4 to €1.55 billion, with growth across all regions. Prurigo nodularis phase 3 trials showed significant improvements.
- Vaccines sales declined 6.5% in Q4 due to earlier seasonal flu shipments, while full year flu vaccine sales reached record levels in 2021.
- Planned launches of sutimlimab for CAD in 2022 and olp
The document outlines SQM, a global mining company based in Chile, and discusses its business lines including being a leading producer of potassium nitrate, iodine, lithium, and industrial chemicals. It highlights SQM's unique natural resources in Chile, sales to over 115 countries, solid financial position, and capital expenditure plans to increase production capacities of various products.
This presentation provides an overview and summary of Johnson & Johnson's 2008 business performance and outlook for 2009. Key points include:
- J&J delivered strong financial results in 2008, meeting guidance targets for sales growth and adjusted earnings per share.
- The company's three business segments - pharmaceuticals, medical devices & diagnostics, and consumer - all experienced sales growth in 2008.
- J&J is advancing its pharmaceutical, medical device, and consumer product pipelines with numerous new product filings planned for 2009-2010.
- While macroeconomic uncertainties may impact 2009 performance, J&J is well positioned due to its diversified business portfolio and continued investment in R&D and new product development.
GNC presented at the William Blair Growth Stock Conference on June 14, 2011. The presentation provided an overview of GNC's business segments including retail, franchise, and manufacturing/wholesale. It highlighted GNC's leading market position in health and wellness retailing in the US and globally. The presentation also discussed positive macro trends driving industry growth, such as increasing focus on health and wellness, and how GNC is well-positioned to capitalize on these trends through its premium branded products and knowledgeable customer service.
We are given a buy recommendation for Gilead Sciences. While Gilead has seen significant revenue growth in recent years due to two hepatitis C drugs, their future revenue growth is expected to slow. Speculation around future performance and new competition has led the market to undervalue Gilead. However, the company maintains a broad product portfolio and pipeline, and low costs provide strong margins. If Gilead can successfully manage competition through new drugs and pricing strategies, while pursuing M&A, they are positioned to outperform current market expectations.
Merck announced second-quarter 2005 earnings per share of 33 cents, down from 79 cents in 2004 due to a $640 million net tax charge. Excluding this charge, EPS were 62 cents. Worldwide sales were $5.5 billion, down 9% from 2004 due to the Vioxx withdrawal. Merck anticipates third-quarter EPS of 61-65 cents and full-year 2005 EPS of $2.44-$2.52 excluding the tax charge. Major drug franchises like Singulair, Fosamax, Cozaar, and Zocor maintained or grew market share. Merck's vaccine and diabetes drug pipelines progressed with regulatory submissions.
Bristol-Myers Squibb reported strong fourth quarter 2008 results, with net sales increasing 4% driven by key products like Plavix, Abilify, and Orencia. Gross profit margins improved significantly due to cost improvements and favorable product mix. Research and development expenses increased to fund new collaborations. The company provided guidance for 2009 GAAP EPS of $1.58-$1.73 and non-GAAP EPS of $1.85-$2.00, expecting revenue growth and further margin improvements. Bristol-Myers will continue business development efforts and advancing its pipeline to create long-term shareholder value.
The document discusses Coca-Cola's strategy and investments to achieve long-term profitable growth through 2020. It highlights growth in emerging markets, executing strategies in developed markets like North America, and investing in core brands and system capabilities globally. Coca-Cola aims to capture opportunities from rising global prosperity while driving sustainable growth across geographic segments.
Laurent Freixe presented on driving sustainable value creation in Zone Americas. Some key points:
1) Zone Americas has a strong footprint across North and Latin America with $37.7 billion in sales and over 90,000 employees.
2) Zone Americas has accelerated organic growth from 3.4% in 2017 to 4.8% in 2020 while reducing structural costs and increasing underlying operating profit margin.
3) Sustainability is at the core of the strategic framework, including initiatives from farm to fork and beyond like regenerative agriculture, renewable energy, and reducing water usage.
The 2008 annual report summarizes Agilent's strong financial performance in fiscal year 2008, with 7% revenue growth to $5.8 billion and increases in operating profit, earnings per share, and return on invested capital. It also discusses Agilent's proactive response to the economic slowdown in the second half of 2008 through cost controls and investment in innovative measurement solutions. The report outlines Agilent's leadership in electronic and bio-analytical measurement and strategy to focus on growth areas like life science, while managing declines in manufacturing test markets during the economic downturn.
Play to Win Q2 2021 Results
- Sanofi reported sales of €8.7 billion in Q2 2021, up 12% year-over-year, and business EPS of €1.38, up 16% year-over-year.
- Dupixent sales grew 57% year-over-year to €1.2 billion, driven by strong performance in both the US and ex-US markets.
- Vaccines sales increased by double digits to €1 billion in Q2 2021 compared to the same period in 2020.
- The presentation reviewed Sanofi's progress on priority R&D assets and initiatives to increase diversity and inclusion in the workplace.
This document summarizes Sanofi's Sustaining Innovation Analyst Day held on December 13, 2017 in Paris. It outlines Sanofi's strategic focus on sustaining innovation in R&D through developing high-value projects, improving launch pipeline and portfolio prioritization processes. Sanofi's R&D model focuses on key disease areas like immunology, oncology, rare diseases, diabetes and vaccines. The presentation highlights 9 potential product submissions in the next 18 months and over 10 new pivotal trials expected to start in the next 12 months. Sanofi aims to financially discipline its R&D investments based on rigorous project prioritization methodology.
The document is a summary of the 2014 Food & Beverage Industry Study by WeiserMazars LLP. It finds that most food and beverage companies anticipated sales growth in 2013 and 2014 due to new customers and improved sales performance. Companies expect costs like labor to rise in 2014. The top concerns for companies are rising commodity costs and food safety. Most companies are prepared for Affordable Care Act requirements and are focusing on process improvement and digital marketing.
This document contains forward-looking statements regarding Sanofi's strategic outlook, key growth drivers, and pipeline of potential transformative therapies. It discusses the significant growth potential of Dupixent across type 2 inflammatory diseases, with an ambition to achieve over €10 billion in peak sales. Vaccines are also highlighted as an expected mid-to-high single-digit growth driver through 2025. The pipeline includes potential first-in-class or best-in-class therapies for diseases like multiple sclerosis, respiratory syncytial virus, and breast cancer that could transform patient care if approved.
This document provides a safe harbor statement noting that certain statements made could constitute forward-looking statements regarding expectations of future operating results and events. It cautions that actual results could differ materially from expectations due to various risks and uncertainties. It also outlines Monster Beverage Corporation's commitment to employee health and safety during the COVID-19 pandemic, including closing offices, providing necessary equipment for remote work, enhanced safety protocols, and increased employee communication and support programs. Finally, it provides data on the company's and category's financial performance in the total US market for the 13 weeks ending December 26, 2020.
Social media allows for two-way communication and dialogue rather than one-way broadcasts. It has seen a rapid rise with key sites like Friendster, MySpace, Facebook, Twitter, and others growing exponentially in their early years. Marketers are drawn to social media because it enables conversations with consumers and viral word-of-mouth at low cost compared to traditional media. However, it also poses challenges for brands to control their message and reputation across fragmented networks.
The document outlines the process for developing and expanding a healthcare provider network. It involves assessing the target market, identifying necessary provider types, designing products to meet regulatory and customer needs, recruiting providers, completing contracts, and marketing the new network. Key steps include determining locations and populations, assessing competitors, recruiting primary care and specialists, complying with regulations, establishing payment rates, collecting signed contracts, and launching promotional materials and events. The goal is to build a network that offers customers valuable healthcare options and providers an attractive partnership.
Kiriasis Savvas, EIPG Greek Delegate
Presentation at Malta Qualified Persons Association-European Industrial Pharmacists Group-University of Malta joint seminar “The Successes And Challenges Of Today’s Pharmaceutical Industry”, Malta 2008.
This document summarizes a presentation given by David Lin from Novartis Oncology on drug purchasing and pricing from the pharmaceutical industry perspective. The presentation covers:
- The growing demand for healthcare and new treatments putting pressure on pricing and access
- Malaysia's national medicine policy and efforts to improve access to medicines through affordability
- Factors considered in pharmaceutical pricing like production costs, reference pricing to other countries, and balancing access and sustainability
- Efforts by industry like access programs to help patients gain early access to innovative treatments
- The changing treatment landscape with new cellular and personalized therapies requiring new frameworks for evaluation and pricing assessment.
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Carlos Betancur Gálvez
Valery Paris, analista senior de Política Sanitaria, División de Salud, de la Organización de Desarrollo y Cooperación Económica (OCDE), ha destacado en su ponencia la importancia de considerar en la asignación de los precios de los medicamentos “los beneficios más allá del sector de la salud”, en referencia al coste de oportunidad y a otras variables económicas de lo que supone la entrada de un medicamento en un determinado mercado. París también ha señalado la dificultad de establecer una política común de asignación de precios en los diferentes países europeos: “Los países no siempre llegan a un acuerdo, por ejemplo, en el grado de innovación de nuevos productos”.
Future of Market Access – a Pharma PerspectivePM Society
The document discusses the future of market access in the pharmaceutical industry from 2002-2022. It notes increasing demands on healthcare systems, financial challenges, and the need for innovation. The future will require different types of market access based on a country's resources. Pharmaceutical companies will need to focus on outcomes, value-based pricing, real-world data, new customers like health boards, and playing a larger role in healthcare beyond just products.
Pistoia Alliance European Conference 2015 - Jo Pisani / PwCPistoia Alliance
The document discusses how the current business model for developing antibiotics is broken, as evidenced by the declining antibiotic pipeline. New approaches are needed to incentivize research and development of new antibiotics given the challenges of demand uncertainty, limited patent windows, and low prices which make antibiotics an unattractive investment. Potential solutions proposed include establishing a global governance body to oversee public-private partnerships for anti-infective development and reimbursement. Other ideas involve rewarding generic companies for stewardship and applying risk sharing models and financial instruments to raise funds for antibiotic research and development.
Impact of Sweeping Changes in Pricing Regulations: Are there rational guidelines to implementation of new PMPRB regulations? Or maybe not?Neil Palmer, PDCI Market Access Inc.
. Rare Disease Day Conference 2020 March 9-10
This engaging webinar will help you learn more about the Patented Medicine Prices Review Board and the impact of their proposed price review reforms. The webinar was moderated by 3Sixty Public Affairs’ Bill Dempster, who was joined by a panel of experts.
Former PMPRB staff member Neil Palmer analyzed the government’s perspectives on the proposed reforms. Carole Watson from Janssen presented a case study outlining the effects of the proposals on a pharmaceutical manufacturer’s decision making regarding the launch of a new cancer medicine and Martine Elias, Executive Director of Myeloma Canada, provided input on the proposed reforms from a patient leader perspective.
A moderated Q&A session allowed participants to provide their perspectives and questions on how the proposed pricing reforms might impact the availability of new innovative treatments in this country.
This is the first in a series of eight CCSN webinars on health technology assessment and drug approval. Stay tuned for further webinars.
The document discusses recent developments regarding product listing agreements (PLAs) with the pan-Canadian Pharmaceutical Alliance (pCPA) and private payers in Canada. It notes that the pCPA office is now operational, which could standardize and improve the negotiation process. It also discusses Quebec recently joining pCPA negotiations, which may lead to more products being listed faster in that province. The document also examines the growing interest of private payers in Canada in negotiating their own PLAs, especially for specialty products, and finds that these agreements will likely become more important and prevalent over time.
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
1. The document discusses opportunities for new therapies in the treatment of posterior segment disorders such as dry age-related macular degeneration (AMD), diabetic macular edema (DME), and others.
2. It finds that dry AMD represents a significant market opportunity as the first drug to successfully target and prevent progression of geographic atrophy would have a major impact, given the large patient population and lack of current treatment options.
3. Key considerations for clinical development include using change in best corrected visual acuity or rate of geographic atrophy progression as the primary endpoint, enrolling patients with intermediate disease severity for at least 2 years, and demonstrating at least a 3-line difference in visual acuity or 20% reduction in
The document contains forward-looking statements about the company's business outlook, future economic performance, and financial projections. These statements are estimates based on currently available information and involve risks and uncertainties that could cause actual results to differ materially. Risks that could affect the accuracy of the forward-looking statements are identified in public filings with the SEC. Forward-looking statements should be considered in light of these risk factors.
Case for emerging 9 sustaining oncology innovationyuvrajgill
The document discusses the challenges facing major oncology innovator companies as their traditional cash cow drugs lose market share to biosimilars. It argues that innovators need to look beyond traditional Western markets and consider partnering with emerging markets like India to strengthen their healthcare systems and generate sustainable revenues. This could help build new cash cows to fund future innovation while improving access in populations with high cancer rates. The document outlines how an integrated approach with partners across government, non-profits and hospitals could work to mutually benefit patients, innovators and healthcare systems in emerging markets.
PDCI is a Canadian consulting firm established in 1996 specializing in pharmaceutical pricing and reimbursement. It has 22 consultants with expertise in both pricing and reimbursement. PDCI helps pharmaceutical companies secure reimbursement coverage by communicating value to payers through evidence-based approaches and leveraging relationships. It offers a range of services including pricing strategies, reimbursement submissions, health economics analyses, and policy research to support clients navigating the Canadian market access environment.
The document discusses the proposed changes to Canada's Patented Medicine Prices Review Board (PMPRB) regulations and their potential impacts. It begins with concerns over implementing drastic price reductions for new prescription medicines during the COVID-19 pandemic. It then provides an overview of the webinar topics, which include perspectives on alternative drug pricing approaches and implications of the PMPRB changes. The changes would lower Canada's drug prices significantly by changing the comparator countries used to set maximum prices and introducing new factors to unilaterally set maximum rebated prices. There are concerns this could reduce patient access to innovative medicines, especially for rare diseases.
pneumoconiosis market is expected to offer significant growth at a CAGR of 9....subishsam
Pneumoconiosis is a lung disease that makes breathing hard and is caused by breathing in dust at work. Pneumoconiosis can be caused by a number of different things that are breathed in. This disease is caused by both organic and inorganic things. The Centers for Disease Control and Prevention say that 260,000 people died from pneumoconiosis in 2013. The market has grown because more people are getting pneumoconiosis, more people are smoking, and air pollution is getting worse. About 75% of the cases of non-asbestos pneumoconiosis that were reported to the IIDB in 2009 were from people over the age of 65. According to the Centers for Disease Control and Prevention, more than 480,000 people die every year in the United States because they smoke cigarettes.
The document provides an outlook on the global bio-pharmaceutical sector in 2011. It discusses factors that are positive for the sector such as increased R&D spending and novel drug approvals. Challenges mentioned include regulatory hurdles, biosimilars, and patent expiries. The document analyzes investment opportunities in areas like HCV, autoimmune diseases, and rare genetic disorders. It also examines issues facing mature biotechs and provides a valuation methodology.
Nutritional Bar Market Report: Industry Outlook, Latest Development and TrendsIMARC Group
According to the latest report by IMARC Group, titled " Nutritional Bar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025," The global nutritional bar market grew at a CAGR of nearly 5% during 2014-2019.
To learn more about this market, visit us at: https://www.imarcgroup.com/nutritional-bar-market
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The report has categorized the market based on vehicle type, propulsion type, application, battery type, battery capacity and region.
For more information, request for a free sample report here: https://www.imarcgroup.com/nutritional-bar-market/requestsample
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
China Pharmaceuticals - Building bridges to innovation - BioCentury China He...Franck Le Deu
This document provides a summary of a McKinsey & Company presentation on the pharmaceutical market in China. It discusses key growth drivers for China's pharmaceutical market, increasing contributions of China to global sales for major pharmaceutical companies, and new commercial models and investments by pharmaceutical companies in China. It also summarizes recent trends impacting the Chinese market such as emerging new commercial models, increasing role of private capital and IT companies, rising quality and innovation among domestic Chinese players, and proposed changes to China's drug reimbursement and pricing policies.
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
This webinar will introduce you to the Patented Medicine Prices Review Board (PMPRB), how they regulate drug pricing in Canada and the proposed changes that will affect cancer patients.
John Babitt, Partner, Life Sciences, Transaction Advisory Services, Ernst & Young LLP, presented at MEDTECH 2014 on The State of Change: A Look at the Evolving Healthcare Landscape and the Effect on Life Science Organizations Today and Tomorrow.
R&D, Competition and Diffusion of Innovation in EU: The Case of Direct Acting...Office of Health Economics
An OHE research studies the role of R&D incentives and market competition in facilitating the diffusion of pharmaceutical innovation across European countries. The research studies the case of the DAA treatments for hepatitis C. Methods and results were presented and discussed at EUHEA conference 2018 held in Maastricht, The Netherlands, 11-14 July. The analysis concludes that (i) R&D incentives may have encouraged in-patent competition of DAAs and (ii) competition had a positive impact on uptake and adoption of DAA treatments in the countries studied (top-5 European plus Portugal).
Author(s) and affiliation(s): Mikel Berdud (OHE), Phill O'Neill (OHE), Martina Garau (OHE), Adrian Towse (OHE)
Conference/meeting: EUHEA Conference 2018
Location: Maastricht, The Netherlands
Date: 12/07/2018
Similar to Canadian Institute Conference - Arvind Mani's Presentation - Final - April 1 2015 (20)